Park You Jeong, Borlongan Cesar V
Department of Neurosurgery and Brain Repair, University of South Florida Morsani College of Medicine, Tampa, USA.
J Cereb Blood Flow Metab. 2021 Oct;41(10):2797-2799. doi: 10.1177/0271678X211026507. Epub 2021 Jun 29.
The last 50 years have witnessed the translation of stem cell therapy from the laboratory to the clinic for treating brain disorders, in particular stroke. From the focal stereotaxic transplantation to the minimally invasive intravenous and intraarterial delivery, stem cells display the ability to replenish injured cells and to secrete therapeutic molecules, altogether promoting brain repair. The increased stroke incidence in COVID-19 survivors poses as a new disease indication for cell therapy, owing in part to the cells' robust anti-inflammatory properties. Optimization of the cell transplant regimen will ensure the safe and effective clinical application of cell therapy in stroke and relevant neurological disorders.
在过去的50年里,干细胞疗法已从实验室走向临床,用于治疗脑部疾病,尤其是中风。从局部立体定向移植到微创静脉和动脉给药,干细胞展现出补充受损细胞以及分泌治疗性分子的能力,共同促进脑修复。新型冠状病毒肺炎(COVID-19)幸存者中风发病率的增加成为细胞治疗的一种新的疾病适应症,部分原因在于细胞强大的抗炎特性。优化细胞移植方案将确保细胞疗法在中风及相关神经疾病中的安全有效临床应用。